Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma — Stella

Home/Gynecologic Cancer/Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

View on ClinicalTrials.gov

Recruiting

Back to Gynecologic Cancer trials

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama

Key details

Phase

Early testing / Safety & dosing

Sponsor

University of Alabama at Birmingham

Enrollment target

~37 participants

Started

August 2023

Primary completion

April 2027

Age range

18 Years and older

Sex

Female only

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.